IR Strategies Around Clinical Trial Success episode artwork

EPISODE · Oct 13, 2025 · 1 MIN

IR Strategies Around Clinical Trial Success

from The Investor Relations Podcast · host Joshua Wilson

In this episode of The Investor Relations Podcast, Michael Loftus, Biotech Growth Architect and Family Office Strategist, shares how biotech companies should approach investor relations conversations around major clinical milestones. He explains why early and proactive engagement is critical, what types of conversations to prioritize before and after approval, and how the current market environment has shifted expectations compared to previous years.The discussion highlights the importance of realistic revenue communication, the risks of overselling financial expectations, and the need for transparency to build trust. Michael emphasizes why biotechs should be talking with investors well before the final approval decision to avoid falling behind and to establish long-term credibility.#InvestorRelations #Biotech #LifeSciences #CapitalMarkets #ClinicalTrials #BiotechInvestingConnect with the GuestCompany: https://www.poccap.comLinkedIn: https://www.linkedin.com/in/mikeloftusclinicaltrials/Podcast profile: View all of their episodes hereConnect with the HostJoshua Wilson LinkedIn: https://www.linkedin.com/in/joshuabrucewilson/The Investor Relations Podcast YouTube channel: https://www.youtube.com/@TheInvestorRelationsPodcastContact Linkhttps://www.theinvestorrelationspodcast.com/contact/Disclaimer: Joshua Wilson is a licensed Florida real estate broker and holds FINRA Series 79 and Series 63 licensure. The content of this podcast is for informational and educational purposes only and should not be considered legal, financial, or compliance advice. All views and opinions expressed by the host and guests are their own and do not necessarily reflect the policies or positions of any regulatory agency, organization, or employer. Listeners should consult their own legal counsel, compliance teams, or financial advisors to ensure adherence to applicable regulations, including SEC, FINRA, and other industry-specific requirements. This podcast does not constitute a solicitation or recommendation for any financial products or services.Let’s Connect on LinkedIn:https://www.linkedin.com/in/joshuabrucewilson/To Contact Us, Please Visit:https://www.theinvestorrelationspodcast.com/contact/

Episode metadata supplied by the publisher feed · Published Oct 13, 2025

Embed this episode

In this episode of The Investor Relations Podcast, Michael Loftus, Biotech Growth Architect and Family Office Strategist, shares how biotech companies should approach investor relations conversations around major clinical milestones. He explains why early and proactive engagement is critical, what types of conversations to prioritize before and after approval, and how the current market environment has shifted expectations compared to previous years. The discussion highlights the importance o...

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

IR Strategies Around Clinical Trial Success

0:00 1:32

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Investor Relations Podcast?

This episode is 1 minute long.

When was this The Investor Relations Podcast episode published?

This episode was published on October 13, 2025.

Is there a transcript available for this episode?

Yes, a full transcript is available for this episode. You can read the complete transcript on the episode page.

Can I download this The Investor Relations Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!